新型非典型抗精神病药:鲁拉西酮

A new atypical antipsychotic drug:lurasidone

鲁拉西酮为一新型非典型抗精神病药,属于苯并异噻唑衍生物,为多巴胺D_2和5-羟色胺2A(5-HT_(2A))受体拮抗剂。2010年10月28日美国食品和药物管理局批准鲁拉西酮上市,其商品名为Latuda,用于治疗成人精神分裂症。鲁拉西酮的有效剂量范围为40～120mg·d^(-1),推荐起始剂量为40mg·d^(-1),一般最大推荐剂量为80mg·d^(-1),应与食物同时服用。鲁拉西酮常见不良反应有嗜睡、静坐不能、恶心、帕金森病以及焦虑。本文对鲁拉西酮的药理作用、药动学、药物相互作用、临床评价和安全性等进行综述。

Lurasidone is an atypical antipsychotic agent approved by the U.S. Food and Drug Administration （FDA） belonging to benzoisothiazol derivatives. It was for treatment of schizophrenia on October 28, 2010. The action mechanism of lurasidone has been suggested that the efficacy is mediated through a combination of central dopamine D2 and 5-HT2A receptor antagonism. Lurasidone is indicated for the treatment of patients with schizophrenia. It has been shown to be effective in the dose range of 40 mg·d^-1 to 120 rag.d% The recommended starting dose is 40 mg·d^-1 and the maximum recommended dose is 80 mg·d^-1. Lurasidone should be taken with food. Adverse reactions associated with the use of lurasidone may include, but are not limited to, the following： somnolence, akathisia, nausea, parkinsonism, aud agitation. The pharmacology, pharmacokinetics, drug interactions, clinical evaluation, and safety of lurasidone are reviewed in this paper.